Deals In Depth: March 2023

Three $1bn+ alliances were penned in March. Topping the list was a potential $1.9bn deal between Moderna and Generation Bio. The collaboration will combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform as the companies seek to expand the application of their platforms by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines.